DePuy ASR Hip Lawsuit

Bernstein Liebhard LLP reports on a February 15, 2012 article published in the New York Times revealing that Johnson & Johnson (“J&J”) continued to sell one model of its DePuy ASR hip replacement implants abroad after the U.S. Food and Drug Administration (“FDA”) rejected J&J’s...

Bernstein Liebhard LLP is pleased to announce the launch of a new video that provides useful information for individuals who were affected by the DePuy ASR hip recall. The video can be found on the Firm’s website, as well as on YouTube. In August 2010, DePuy Orthopaedics, a subsidiary of Johnson &...

On February 4, 2012, The Sunday Telegraph reported that metal-on-metal hip implants may be linked to cancer. According to The Telegraph, next month researchers from the University of Bristol will present their findings at the British Hip Society conference. Researchers participating in the study con...

Recently, the U.S. Food and Drug Administration (“FDA”) has been repeatedly criticized by the media, experts and congressmen for its medical device approval process. Calls for regulatory reform have been become commonplace given the wave of medical devices approved by the FDA that have since pro...

PRESS RELEASE: On January 30, 2012, Bernstein Liebhard LLP reported that health regulators in Britain are concerned that recipients of the metal-on-metal DePuy ASR hip implants were never notified that the devices were recalled.  In August 2010, DePuy Orthopaedics, a subsidiary of Johnson & ...

When first introduced to the market, metal-on-metal artificial joints, such as the DePuy hip replacement implants were expected to last longer than traditional implants, which combined metal and polyethylene.  However, recent studies have identified a range of problems commonly associated with meta...

On January 23, 2012, the Honorable David A. Katz held a status conference in In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation (“MDL No. 2197”), which is currently underway in the U.S. District Court for the Northern District of Ohio.  In 2010, DePuy issued a worldwi...

PRESS RELEASE: Bernstein Liebhard LLP reports that on December 8, 2011, the U.S. Food and Drug Administration (“FDA”) sent a warning letter to Johnson & Johnson subsidiary, DePuy Orthopaedics, to stop selling joint replacements that have not been properly approved by the FDA.  According...

PRESS RELEASE: Bernstein Liebhard LLP reports on a new law that would compel drug and medical device manufacturers to disclose any money paid to doctors for research, speaking, consulting, travel and entertainment.  According to a January 17, 2012 article published in the New York Times, under t...

PRESS RELEASE: Bernstein Liebhard LLP reports that on January 12, 2012, a series of additional depositions of DePuy Orthopeadic executives were noticed in In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation (“MDL No. 2197”), which is currently underway in the U.S. D...